The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will organize a virtual meeting on 1-3 December 2021. The theme of the meeting is ‘Emerging Frontiers and Opportunities: Special Populations and Technologies’.
At ISPOR 2021, HARMONY Partner NICE, National Institute for Health and Care Excellence, is presenting two abstracts:
Above and Beyond: Assessing the Nature and Impact of Additional Considerations Above Clinical and Cost Effectiveness by 8 HTA Agencies for a Rare Disease Area
— Direct link to final abstract >
— Direct link to final poster >
Do We Need to Mind the Gap: An Analysis of the Evidence Base Differences and Alignment across Regulator and HTA Agencies
— Direct link to the final abstract >
— Direct link to the final poster >
Both abstracts will be published in the ISPOR journal 'Value in Health', Volume 24, Issue 12, S2, to be released in December 2021.
HARMONY Alliances, uniting stakeholders in the hematology field
With more than 100 Partners and Associated Members from 18 European countries, the HARMONY Alliance can draw on the expertise from academic institutions, clinical networks, patient advocacy groups, pharmaceutical companies, regulatory agencies, and HTA bodies.
HARMONY and Health Economics and Outcomes Research
Regulatory agencies and health technology assessment bodies require robust evidence to show that a drug treatment is both effective and safe. In the case of rare diseases, it may be difficult for researchers to generate sufficient evidence, especially on how effective the treatment is compared with other available treatments. The lack of evidence may hinder market access and the subsequent reimbursement of treatments for these conditions, and slow down or even block patient access to novel treatments. The HARMONY Alliance aims to help researchers to develop appropriate mitigation strategies for new treatments for Hematological Malignancies
Virtual ISPOR Europe 2021, the leading European conference for HEOR
In recent years, rare diseases, digital therapeutics, personalized medicine, cell and gene therapies, and other new therapeutic approaches have stretched our data and methodological capabilities. Furthermore, issues associated with these special populations and technologies have important implications for a range of healthcare decisions, from regulatory pathways to coverage, reimbursement, and shared clinical decision making. ISPOR Europe 2021 will feature scientists and stakeholders who work on these key challenges and highlight innovative solutions, as well as examples of how partnerships and dialogue with other disciplines are contributing to address these issues.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on various Hematologic Malignancies. The HARMONY Alliance, funded by Innovative Medicines Initiative, unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. The aim is to accelerate the development of more effective treatments. Data are stored in HARMONY’s Big Data Platform, which has already identified over 80,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!